Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Marso

Showing results (101-110 of 143) with videos related to

Pageof 15
Sort By:
JACC. Cardiovascular Interventions|November 21, 2009
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registryJason B Lindsey, Steven P Marso, Michael Pencina, et al.
American Heart Journal|September 7, 2016
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1Steven P Marso, Darren K McGuire, Bernard Zinman, et al.
Journal of the American Heart Association|October 14, 2015
Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic ReviewAmbarish Pandey, Sushil Garg, Susan A Matulevicius, et al.
Circulation. Cardiovascular Interventions|June 13, 2020
Management of Percutaneous Coronary Intervention Complications: Algorithms From the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications ConferenceJacob A Doll, Ravi S Hira, Kathleen E Kearney, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 11, 2010
Intravascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score: an analysis from a global IVUS registrySteven P Marso, Andrew D Frutkin, Sameer K Mehta, et al.
Journal of the American College of Cardiology|May 19, 2012
Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI RegistrySumeet Subherwal, Eric D Peterson, David Dai, et al.
The American Journal of Cardiology|May 15, 2012
Relation between angiographic lesion severity, vulnerable plaque morphology and future adverse cardiac events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study)Kyeong Ho Yun, Gary S Mintz, Naim Farhat, et al.
Diabetes, Obesity & Metabolism|September 30, 2020
Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
Diabetes, Obesity & Metabolism|April 7, 2020
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)Richard E Pratley, Scott S Emerson, Edward Franek, et al.
Pageof 15

Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
JACC. Cardiovascular Interventions|November 21, 2009
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registryJason B Lindsey, Steven P Marso, Michael Pencina, et al.
American Heart Journal|September 7, 2016
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1Steven P Marso, Darren K McGuire, Bernard Zinman, et al.
Journal of the American Heart Association|October 14, 2015
Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic ReviewAmbarish Pandey, Sushil Garg, Susan A Matulevicius, et al.
Circulation. Cardiovascular Interventions|June 13, 2020
Management of Percutaneous Coronary Intervention Complications: Algorithms From the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications ConferenceJacob A Doll, Ravi S Hira, Kathleen E Kearney, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 11, 2010
Intravascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score: an analysis from a global IVUS registrySteven P Marso, Andrew D Frutkin, Sameer K Mehta, et al.
Journal of the American College of Cardiology|May 19, 2012
Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI RegistrySumeet Subherwal, Eric D Peterson, David Dai, et al.
The American Journal of Cardiology|May 15, 2012
Relation between angiographic lesion severity, vulnerable plaque morphology and future adverse cardiac events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study)Kyeong Ho Yun, Gary S Mintz, Naim Farhat, et al.
Diabetes, Obesity & Metabolism|September 30, 2020
Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
Diabetes, Obesity & Metabolism|April 7, 2020
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)Richard E Pratley, Scott S Emerson, Edward Franek, et al.
Pageof 15